论文部分内容阅读
目的评估“三亚共识”对原发性肝癌肝移植治疗的临床价值。方法回顾性分析2003年4月至2006年1月间第二军医大学东方肝胆外科医院收治的75例因原发性肝癌接受原位肝移植病人,对其与各种肝移植标准的匹配情况进行研究。结果全部75例病人术后1、2、3年的总体存活率及无瘤存活率分别为85%、74%、67%和80%、74%、66%。“三亚共识”组术后1、2、3年总体存活率及无瘤存活率分别为92%、88%、74%、和92%、88%、72%。“三亚共识”与其他三种标准相比术后总体存活率及无瘤存活率差异均无统计学意义。结论“三亚共识”是一种有效的筛选标准。“三亚共识”与UCSF标准可能更适用于目前中国的肝癌肝移植筛选。
Objective To evaluate the clinical value of Sanya Consensus in the treatment of primary liver cancer with liver transplantation. Methods A retrospective analysis of 75 patients with primary liver cancer undergoing orthotopic liver transplantation admitted to the Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University from April 2003 to January 2006 was performed. The matching with various liver transplantation standards was retrospectively analyzed the study. Results Overall survival and tumor-free survival of all 75 patients at 1, 2 and 3 years after operation were 85%, 74%, 67% and 80%, 74% and 66%, respectively. Overall survival and tumor-free survival at 1, 2, and 3 years after operation in Sanya consensus group were 92%, 88%, 74%, and 92%, 88% and 72%, respectively. “Sanya consensus ” compared with the other three standards of postoperative overall survival and tumor-free survival differences were not statistically significant. Conclusion “Sanya consensus ” is an effective screening criteria. “Sanya consensus ” and UCSF standards may be more suitable for China’s liver cancer liver transplantation screening.